BMS' Opdivo gets green light for UK early access scheme
This article was originally published in Scrip
In what appears to be only the second such decision by the UK regulator, the MHRA, Bristol-Myers Squibb's advanced melanoma product Opdivo (nivolumab) has been given the go-ahead to enter the Early Access to Medicines Scheme (EAMS), meaning it can be made available in advance of its EU approval.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.